Roman N Rodionov1, Jens Martens-Lobenhoffer2, Silke Brilloff1, Bernd Hohenstein3, Natalia Jarzebska4, Normund Jabs1, Anja Kittel5, Renke Maas5, Norbert Weiss1, Stefanie M Bode-Böger2. 1. University Center for Vascular Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 2. Institute of Clinical Pharmacology, Otto-von-Guericke University, Magdeburg, Germany. 3. Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 4. Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 5. Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Abstract
BACKGROUND: Asymmetric and symmetric dimethylarginines (ADMA and SDMA) predict complications and mortality in cardiovascular and renal diseases. Alanine:glyoxylate aminotransferase 2 (AGXT2) can metabolize both ADMA and SDMA; however, this metabolic pathway is still poorly understood. The goal of our study was to test the hypothesis that AGXT2 is compensatory upregulated in the settings of ADMA overload and bilateral nephrectomy. METHODS: ADMA was infused for 3 days using osmotic minipumps in mice. Half of the mice underwent bilateral nephrectomy 24 h before the end of the infusion. RESULTS: Infusion of ADMA caused a 3- to 4-fold increase in plasma and urine ADMA levels and a 2- to 3-fold increase in plasma and urine levels of the ADMA-specific metabolite of AGXT2 α-keto-δ-(N,N-dimethylguanidino)valeric acid (DMGV). Bilateral nephrectomy led to an ∼4-fold increase of plasma SDMA levels, but did not change plasma ADMA levels. Interestingly, plasma levels of DMGV were elevated 32-fold in the mice, which underwent bilateral nephrectomy. Neither bilateral nephrectomy nor ADMA infusion caused upregulation of AGXT2 expression or activity. CONCLUSIONS: Our data demonstrate that short-term elevation of systemic levels of ADMA leads to a dramatic increase of DMGV formation without upregulation of AGXT2 expression or activity, which suggests that AGXT2-mediated pathway of ADMA metabolism is not saturated under normal conditions and may play a major role in the maintenance of ADMA homeostasis in the setting of local or systemic elevation of ADMA levels.
BACKGROUND: Asymmetric and symmetric dimethylarginines (ADMA and SDMA) predict complications and mortality in cardiovascular and renal diseases. Alanine:glyoxylate aminotransferase 2 (AGXT2) can metabolize both ADMA and SDMA; however, this metabolic pathway is still poorly understood. The goal of our study was to test the hypothesis that AGXT2 is compensatory upregulated in the settings of ADMA overload and bilateral nephrectomy. METHODS:ADMA was infused for 3 days using osmotic minipumps in mice. Half of the mice underwent bilateral nephrectomy 24 h before the end of the infusion. RESULTS: Infusion of ADMA caused a 3- to 4-fold increase in plasma and urine ADMA levels and a 2- to 3-fold increase in plasma and urine levels of the ADMA-specific metabolite of AGXT2 α-keto-δ-(N,N-dimethylguanidino)valeric acid (DMGV). Bilateral nephrectomy led to an ∼4-fold increase of plasma SDMA levels, but did not change plasma ADMA levels. Interestingly, plasma levels of DMGV were elevated 32-fold in the mice, which underwent bilateral nephrectomy. Neither bilateral nephrectomy nor ADMA infusion caused upregulation of AGXT2 expression or activity. CONCLUSIONS: Our data demonstrate that short-term elevation of systemic levels of ADMA leads to a dramatic increase of DMGV formation without upregulation of AGXT2 expression or activity, which suggests that AGXT2-mediated pathway of ADMA metabolism is not saturated under normal conditions and may play a major role in the maintenance of ADMA homeostasis in the setting of local or systemic elevation of ADMA levels.
Authors: Jeremy M Robbins; Matthew Herzig; Jordan Morningstar; Mark A Sarzynski; Daniel E Cruz; Thomas J Wang; Yan Gao; James G Wilson; Claude Bouchard; Tuomo Rankinen; Robert E Gerszten Journal: JAMA Cardiol Date: 2019-07-01 Impact factor: 14.676
Authors: Ilkka Seppälä; Marcus E Kleber; Steve Bevan; Leo-Pekka Lyytikäinen; Niku Oksala; Jussi A Hernesniemi; Kari-Matti Mäkelä; Peter M Rothwell; Cathie Sudlow; Martin Dichgans; Nina Mononen; Efthymia Vlachopoulou; Juha Sinisalo; Graciela E Delgado; Reijo Laaksonen; Tuomas Koskinen; Hubert Scharnagl; Mika Kähönen; Hugh S Markus; Winfried März; Terho Lehtimäki Journal: Sci Rep Date: 2016-03-17 Impact factor: 4.379
Authors: Juliane Hannemann; Julia Zummack; Jonas Hillig; Leonard Rendant-Gantzberg; Rainer Böger Journal: J Clin Med Date: 2022-02-11 Impact factor: 4.241
Authors: Dmitry V Burdin; Alexey A Kolobov; Chad Brocker; Alexey A Soshnev; Nikolay Samusik; Anton V Demyanov; Silke Brilloff; Natalia Jarzebska; Jens Martens-Lobenhoffer; Maren Mieth; Renke Maas; Stefan R Bornstein; Stefanie M Bode-Böger; Frank Gonzalez; Norbert Weiss; Roman N Rodionov Journal: Sci Rep Date: 2016-10-18 Impact factor: 4.379
Authors: Carolina Averta; Elettra Mancuso; Rosangela Spiga; Sofia Miceli; Elena Succurro; Teresa Vanessa Fiorentino; Maria Perticone; Gaia Chiara Mannino; Prapaporn Jungtrakoon Thamtarana; Angela Sciacqua; Giorgio Sesti; Francesco Andreozzi Journal: Front Cardiovasc Med Date: 2022-01-03